MRK--
PFE--
TEVA--
XLV--
A 100% tariff on patented drugs would shake up the pharma business model Big names facing pressure: $PFE ($28.24, -0.95%) $MRK ($120.22, +0.01%) → Possible margin squeeze as prices go up and pricing options shrink Potential winners: Generic drugs like $TEVA might gain market share as buyers seek cheaper options Broader market effects: Healthcare ETF $XLV ($146.71, -0.62%) might see more swings as the sector adjusts to new risks Could push manufacturing to cheaper regions Might even spark new biotech innovation to handle cost pressures This isn’t just a headline — it’s a big shift that could change pharma economics if it lasts.

Comments



Add a public comment...
No comments

No comments yet

Disclaimer: The above is a summary showing certain market information. Ainvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing, All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market.Report an Issue